Vasoactive intestinal peptide decreases inflammation and tight junction disruption in experimental necrotizing enterocolitis
Topic overview
This murine study demonstrates that exogenous vasoactive intestinal peptide (VIP) administration reduces NEC severity by decreasing inflammatory markers (IL-6, TNF-α) and preserving tight junction integrity (Claudin-3). The findings suggest VIP may offer therapeutic benefit in neonatal NEC by mitigating intestinal barrier disruption.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Vasoactive intestinal peptide decreases inflammation and tight junction disruption in experimental necrotizing enterocolitis. GlobalCastMD Medical Library. 2019-10-23. https://library.globalcastmd.com/article/1745
Comments